Collegium's $65M-$75M Azstarys Target Is Bullish-Jornay PM Is the Safety Net

Collegium's rerating now depends on ADHD scaling fast enough

This quarter is the real test for Collegium. The thesis is no longer just about launching a new product; it is about whether ADHD can grow fast enough to offset the slower pain franchise. The baseline is familiar: can the company hold $199.9 million in Q2 revenue while JORNAY PM revenue rose 41% to $46.1 million and the pain segment remained $140.9 million under pressure? Management has already raised the bar by lifting the partial-year AZSTARYS outlook to $65 million-$75 million. That makes this quarter less about promise and more about proof.

What investors are really judging

Bulls see a better revenue mix. JORNAY PM is still gaining traction, and Azstarys already produced $12.9 million in the quarter in roughly six weeks of sales. Bears, meanwhile, are focused on the offset: the pain portfolio may still be a cushion, but it is not helping if Nucynta-related pressure keeps weighing on results.

The key question is not whether ADHD is growing. It is whether ADHD can generate enough incremental revenue to outweigh a mature franchise that is giving back less over time.

Jornay PM and the pain business are still carrying different jobs

Why the split matters more than the headline

A combined revenue total can obscure what is happening under the surface. For Collegium, the better lens is functional: is the newer ADHD engine producing enough visible demand, while the legacy pain business still supports the model instead of becoming a drag?

That is why the make-or-break issue this quarter is not just top-line stability. It is whether the newer product is scaling quickly enough to change how the market thinks about the company.

Azstarys has early traction and a long runway

Azstarys is still early. It generated $12.9 million in the quarter, which reflected only a partial period of selling. Even so, the commercial setup looks clean. Azstarys has expected patent protection through 2037, so the team has a long window to build share without a near-term patent cliff in the model.

That does not mean execution is guaranteed. It means the business has both an early demand signal and a reasonable amount of time to turn that signal into a durable revenue stream.

The proof points that matter next

The market is no longer paying only for ADHD potential. It is paying for evidence that the new engine is scaling fast enough to offset the older franchise. That is why the next update matters so much: investors need to see that the raised target is being earned, not merely hoped for.

What would keep the bull case intact

• Azstarys trajectory: Reported sales need to track toward the raised $65 million-$75 million partial-year outlook, not just start with a strong debut.
• JORNAY PM continuity: The established ADHD franchise still needs to support the mix while Azstarys scales.
• Guidance credibility: The broader model needs to stay consistent with the company's raised expectations, including the $865 million-$895 million 2026 revenue range and $475 million-$500 million adjusted EBITDA range.

What could weaken the story

Bears already have a clear lever. Collegium said the pain portfolio remains a solid base, but also flagged increased pressure on Nucynta franchise revenues. If that pressure deepens, even solid ADHD growth could look more like offsetting older weakness than creating a true rerating.

The practical test is straightforward. If management can defend the raised guidance bands while showing Azstarys moving in the right direction, the second-engine thesis stays credible. If not, the market may keep treating Azstarys as a promising asset that still needs more time.